公开(公告)号：US20240350477A1

公开(公告)日：2024-10-24

申请号：US18359214

申请日：2023-07-26

申请人： Exelixis, Inc.

发明人： Dana T. Aftab ,  Gisela Schwab ,  Colin Hessel ,  Christian Scheffold ,  Steven Lacy ,  Dale Miles ,  Alan Arroyo ,  Mark Dean

IPC分类号： A61K31/47 ,  A61K9/20 ,  A61K9/28 ,  A61K31/16 ,  A61P35/00

CPC分类号： A61K31/47 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2866 ,  A61K31/16 ,  A61P35/00

摘要： The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.

公开(公告)号：US20240350415A1

公开(公告)日：2024-10-24

申请号：US18660021

申请日：2024-05-09

申请人： CHEMO RESEARCH, S.L.

发明人： Enrico COLLI

IPC分类号： A61K9/20 ,  A61K31/567 ,  A61K47/26 ,  A61K47/32 ,  A61P15/18

CPC分类号： A61K9/2054 ,  A61K31/567 ,  A61K47/26 ,  A61K47/32 ,  A61P15/18

摘要： The invention relates to a new modified release oral pharmaceutical form comprising 17α-cyanomethyl-17-ß-hydroxyestra-4,9-dien-3-one (dienogest) and 17α-ethinylestradiol (ethynyl estradiol), its method of production and its medical and non-medical uses, in particular its use in contraception.

公开(公告)号：US12122815B2

公开(公告)日：2024-10-22

申请号：US17279266

申请日：2019-09-24

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Hiroshi Imoto ,  Mari Adachi ,  Yoko Kanematsu ,  Taiji Asami ,  Ayumu Niida ,  Naoki Nishizawa ,  Derek Cecil Cole ,  Mack Flinspach ,  Nick Scorah ,  Abhijit Suresh Bhat

IPC分类号： C07K14/575 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K38/00 ,  A61K47/02 ,  A61P1/08

CPC分类号： C07K14/575 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2059 ,  A61K47/02 ,  A61P1/08 ,  A61K38/00

摘要： The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 328-893.

公开(公告)号：US12121549B2

公开(公告)日：2024-10-22

申请号：US16642741

申请日：2017-08-29

申请人： BGI SHENZHEN

发明人： Zhuye Jie ,  Suisha Liang ,  Huihua Xia ,  Yuanqiang Zou ,  Liang Xiao ,  Huijue Jia

IPC分类号： A61K35/74 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  A61K45/06 ,  A61P9/10

CPC分类号： A61K35/74 ,  A61K9/0053 ,  A61P9/10 ,  A61K9/20 ,  A61K9/48 ,  A61K45/06

摘要： The present invention discloses an application of Alistipes shahii in preparing a composition for preventing and/or treating lipid metabolism related diseases, for example but not limited to, atherosclerosis related diseases, cardiovascular diseases and obesity.

公开(公告)号：US20240342081A1

公开(公告)日：2024-10-17

申请号：US18637281

申请日：2024-04-16

申请人： Lyndra Therapeutics, Inc.

发明人： Andrew BELLINGER ,  Rosemary KANASTY ,  Tyler GRANT ,  Colin GARDNER

IPC分类号： A61K9/00 ,  A61K9/14 ,  A61K9/20 ,  A61K47/34 ,  A61K47/46 ,  A61M31/00 ,  C08G18/12 ,  C08G18/42 ,  C08G18/73

CPC分类号： A61K9/0065 ,  A61K9/146 ,  A61K9/20 ,  A61K47/34 ,  A61K47/46 ,  A61M31/002 ,  C08G18/12 ,  C08G18/4202 ,  C08G18/4277 ,  C08G18/73

摘要： The invention provides gastric residence systems with configurations and geometrical dimensions that allow for improved shelf life during prolonged storage, and optimal residence properties when the systems are deployed in the stomach of a patient.

公开(公告)号：US12115257B2

公开(公告)日：2024-10-15

申请号：US16612061

申请日：2018-05-09

申请人： UNIVERSITE DE BORDEAUX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT POLYTECHNIQUE DE BORDEAUX ,  ECOLE NATIONALE SUPERIEURE D'ARTS ET METIERS ,  UNIVERSITÉ PARIS CITÉ ,  PARIS SCIENCES ET LETTRES ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE

发明人： Virginie Busignies-Goddin ,  Pascal Bigey ,  Christine Charrueau ,  Virginie Escriou ,  Pierre Tchoreloff

IPC分类号： A61K9/127 ,  A61K9/19 ,  A61K9/20 ,  A61K31/7088 ,  A61P1/04

CPC分类号： A61K9/1272 ,  A61K9/19 ,  A61K9/2018 ,  A61K31/7088 ,  A61P1/04

摘要： The invention relates to a process for the manufacture of a tablet comprising a nucleic acid vector.

公开(公告)号：US20240335460A1

公开(公告)日：2024-10-10

申请号：US18578646

申请日：2022-07-12

申请人： STABICAN B.V.

发明人： Robin DE BRUIJN

IPC分类号： A61K31/00 ,  A61K9/00 ,  A61K9/20 ,  A61K9/50

CPC分类号： A61K31/658 ,  A61K9/0002 ,  A61K9/2081 ,  A61K9/5089

摘要： The invention relates to a process for preparing cannabinoid-containing particles, wherein first a solution is provided wherein the solvent has a water solubility in the range of 2-100 g/L at 25° C. and wherein the solution comprises 1) a cannabinoid component comprising one or more cannabinoids; and 2) a shell-forming component comprising one or more compounds selected from the group of C10-C30 fatty alcohols. C10-C30 fatty acids and esters of C10-C30 fatty alcohols and C10-C30 fatty acids. Then, droplets of the solution are generated in an aqueous medium and the solvent is allowed to migrate from the droplets to the aqueous medium to thereby form solid particles wherein a shell of shell-forming component encapsulates the cannabinoid component.

公开(公告)号：US20240335450A1

公开(公告)日：2024-10-10

申请号：US18745080

申请日：2024-06-17

申请人： Celgene Corporation ,  SERVIER PHARMACEUTICALS LLC

发明人： Sreenivas S. Bhat ,  Scott Burnside ,  Darshan Parikh ,  Chong-Hui Gu ,  Syed Altaf

IPC分类号： A61K31/53 ,  A61K9/20 ,  A61K9/28

CPC分类号： A61K31/53 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2077 ,  A61K9/2095 ,  A61K9/28

摘要： Provided herein is a tablet comprising 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240335390A9

公开(公告)日：2024-10-10

申请号：US18028651

申请日：2021-09-29

申请人： Shenzhen Pharmacin Co., Ltd.

发明人： Zeren WANG ,  Shun CHEN ,  Longwei SUN ,  Yanxin ZHAO

IPC分类号： A61K31/519 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/4725 ,  A61K31/517 ,  A61K31/5377

CPC分类号： A61K9/4866 ,  A61K9/14 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/4816 ,  A61K9/485 ,  A61K9/4858 ,  A61K31/4725 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K47/02 ,  A61K47/12 ,  A61K47/32 ,  A61P35/00

摘要： An amorphous solid dispersions comprising an active pharmaceutical ingredient and pharmaceutical compositions comprising the amorphous solid dispersions. Also described herein are methods for preparing and using such compositions. In some embodiments, an amorphous solid dispersion comprises an active pharmaceutical ingredient such as palbociclib or neratinib, one or more acids, and a high-molecular weight material.

公开(公告)号：US12109216B2

公开(公告)日：2024-10-08

申请号：US18421914

申请日：2024-01-24

申请人： Essentialis, Inc.

发明人： Neil M. Cowen

IPC分类号： A61K31/549 ,  A61K9/00 ,  A61K9/20 ,  A61K9/50 ,  A61K31/137 ,  A61K31/155 ,  A61K31/551 ,  A61K38/27 ,  A61K45/06 ,  C07D285/18 ,  C07D285/22

CPC分类号： A61K31/549 ,  A61K9/00 ,  A61K9/0004 ,  A61K9/2054 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K31/137 ,  A61K31/155 ,  A61K31/551 ,  A61K38/27 ,  A61K45/06 ,  C07D285/18 ,  C07D285/22 ,  A61K2300/00 ,  A61K31/549 ,  A61K2300/00 ,  A61K38/27 ,  A61K2300/00 ,  A61K31/155 ,  A61K2300/00 ,  A61K31/551 ,  A61K2300/00 ,  A61K31/137 ,  A61K2300/00

摘要： Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.